50 related articles for article (PubMed ID: 16029222)
21. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
Toda T; Eliasson E; Ask B; Inotsume N; Rane A
Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
[TBL] [Abstract][Full Text] [Related]
22. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
23. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
[TBL] [Abstract][Full Text] [Related]
24. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
25. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
26. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Mc Donnell CG; Shorten G; Van Pelt FN
Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
[TBL] [Abstract][Full Text] [Related]
27. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
28. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence.
Poulsen TS; Vinholt P; Mickley H; Korsholm L; Kristensen SR; Damkier P
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):103-10. PubMed ID: 15679472
[TBL] [Abstract][Full Text] [Related]
29. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological interactions of statins.
Paoletti R; Corsini A; Bellosta S
Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
[TBL] [Abstract][Full Text] [Related]
31. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A; Holdaas H
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Igel M; Sudhop T; von Bergmann K
Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
[TBL] [Abstract][Full Text] [Related]
34. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus MR
Pharmacotherapy; 2004 Feb; 24(2):285-90. PubMed ID: 14998226
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression.
Fisslthaler B; Michaelis UR; Randriamboavonjy V; Busse R; Fleming I
Biochim Biophys Acta; 2003 Feb; 1619(3):332-9. PubMed ID: 12573493
[TBL] [Abstract][Full Text] [Related]
37. [Undesirable drug interactions of hypolipemic drugs].
Chojnowska-Jezierska J
Pol Merkur Lekarski; 2000 Sep; 9(51):618-20. PubMed ID: 11126989
[TBL] [Abstract][Full Text] [Related]
38. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.
Cummins CL; Wu CY; Benet LZ
Clin Pharmacol Ther; 2002 Nov; 72(5):474-89. PubMed ID: 12426511
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
